Barclays analyst Glen Santangelo raised the price target for Dentsply Sirona (NASDAQ: XRAY) from $9 to $11. The firm maintained its Underweight rating on the dental technology company.

The adjustment reflects a modest upward revision in valuation expectations, though the negative stance remains unchanged. No specific catalysts or operational metrics were cited in the brief update.

Dentsply Sirona Inc. returned to profitability in the second quarter of 2026, reporting net income attributable to shareholders of $37 million, compared to a net loss of $45 million in the second quarter of 2025. The company simultaneously reaffirmed its full-year 2026 adjusted earnings per share (EPS) guidance of $1.40 to $1.50, which sits below the $1.42 analyst estimate, and its net sales outlook of $3.5 billion to $3.6 billion, slightly under the $3.582 billion consensus. This turnaround was primarily driven by an expansion in GAAP gross margin to 54.9%, up from 52.4% in the prior-year period, offsetting a 4.1% year-over-year decline in net sales to $898 million.

GAAP diluted EPS stood at $0.18, reversing a loss of $0.22 per share recorded in the second quarter of 2025. On a non-GAAP basis, adjusted EPS remained flat at $0.52, down slightly by 1.6% constant currency, while adjusted EBITDA margin improved modestly to 21.3% from 21.1% in the prior year. Operating cash flow surged to $99 million from $48 million in the previous year, bolstered by approximately $44 million in tariff refunds and better working capital management. Free cash flow rose significantly to $55 million, compared to $16 million in the second quarter of 2025.

Segment Performance

Sales declines were broad-based across most segments, though Wellspect Healthcare emerged as a growth bright spot. Essential Dental Solutions, the largest segment, saw sales drop 2.7% to $376 million. Orthodontic and Implant Solutions experienced a sharper contraction, with sales falling 13.2% to $197 million, heavily impacted by a 27.1% decline in the EMEA region. Connected Technology Solutions revenue decreased 1.5% to $239 million. In contrast, Wellspect Healthcare sales grew 7.1% to $86 million, driven by double-digit growth in both the EMEA and APAC regions.

Strategic Updates and Outlook

Dentsply Sirona announced an expanded partnership with Medline Sinclair to broaden access to its Connected Technology Solutions portfolio across Canada. During the quarter, the company repurchased 1.3 million shares of common stock for approximately $12 million. As of June 30, 2026, cash and cash equivalents stood at $239 million.

Management reiterated its 2026 full-year outlook, projecting net sales in the range of $3.5 billion to $3.6 billion and adjusted EPS between $1.40 and $1.50. The company noted that benefits from tariff refunds are not included in the adjusted EPS guidance. President and CEO Dan Scavilla emphasized that the company is making meaningful progress in high-priority areas, including reinvesting in the business to drive sustained, profitable growth.

What the Numbers Show

The divergence between reported GAAP results and non-GAAP metrics highlights the impact of prior-year comparables. The significant year-over-year improvement in net income was largely aided by the absence of the $235 million in goodwill and intangible asset impairments that weighed on results in the second quarter of 2025. While top-line revenue contracted, the expansion in gross profit to $493 million from $490 million indicates successful cost containment and margin optimization efforts are yielding results even in a challenging sales environment. The affirmed guidance suggests management expects these margin gains to persist despite continued top-line headwinds.